New release date for Sedana Medical’s year-end report 2018
Regulatory
Sedana Medical AB (publ) announce today that the year-end report for 2018 will be released Tuesday 12th of March 2019 at 07.00 CET instead of 21st of March.
Sedana Medical establishes sedation research foundation
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the establishment of the Sedana Medical Research Foundation, creating a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pati…
Sedana Medical receives go-ahead for pediatric study - Milestone on the road to market exclusivity
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces the company has been approved for its planned pediatric study from the Pediatric Committee of EMA, European Medicines Agency, (PDCO).
Amendment of previously announced press release Sedana Medical AB (publ), Sedana Medical’s nomination committee appointed
Regulatory
In the previously announced press release the following text was included: This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure…
Sedana Medical’s nomination committee appointed
Regulatory
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 22, 2018, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…
Sedana Medical AB (publ), Interim report Q3, 2018
Regulatory
Strong development towards our strategic objectives
Sedana Medical shows significant health-economic benefits with AnaConDa
Non-regulatory
Sedana Medical AB (publ) (Sedana Medical or the company) presents a health economic analysis at the European Conference for Health Economics and Outcomes Research 2018 (ISPOR) in Barcelona, showing clinical and economic benefits of inhaled isoflurane…
Sedana Medical receives approval for AnaConDa in Japan
Regulatory
Sedana Medical AB (publ) (Sedana Medical or the company) announces today that the company has received market approval for AnaConDa from the Ministry of Health, Labour and Welfare (MHLW) in Japan. Through the approval, AnaConDa can now be marketed,…
Sedana Medical AB (publ) – The first direct sales of AnaConDa in Great Britain.
Non-regulatory
Sedana Medical AB (publ) (Sedana Medical or Company) has established its own sales organization in Great Britain, in accordance with the previously announced plan. The Company is now delivering its first direct deliveries of AnaConDa for sedation of…
Completed sale of shares in Sedana Medical AB (publ)
Regulatory
Sedana Medical AB (publ) (“Sedana Medical”) broadens the shareholder base through a secondary sale of existing shares by four insiders to Handelsbanken Fonder, Apus Capital, Norron Asset Management and Brohuvudet AB (the “Block Sale”). The Block Sale…
Correction of previously announced press release Sedana Medical AB (publ), Interim report Q2, 2018
Regulatory
In the press release published 30 August 07:00 CET the following has been reported: · EBITDA amounted to 1 794 (1 081) KSEK and the EBITDA margin was -6,0% (5,6%). Correct reporting is: · EBITDA amounted to -1 794 (1 081) KSEK and the EB…
Sedana Medical AB (publ), Interim report Q2, 2018
Regulatory
The registration process for the United States commenced and European study resumed at full speed
Sedana Medical to host conference call to provide second quarter 2018 business update
Non-regulatory
On August 30, 2018, at 07:00 am CET, Sedana Medical AB (publ) (Sedana Medical or the Company) will publish its interim report for the second quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which wil…
Sedana Medical AB (publ) resumes pivotal phase 3-study IsoConDa with full patient recruitment rate.
Regulatory
Sedana Medical AB (publ) (Sedana Medical or the Company) announces today that the Company has received approval from the central ethical committee for its pivotal phase 3-study in Germany, IsoConDa, to continue to use the original study protocol afte…
Sedana Medical AB (publ) recruits Global Marketing Director
Regulatory
Sedana Medical AB (publ), developing and marketing the medical device AnaConda and volatile anesthetics for sedation of mechanically ventilated intensive care unit (ICU) patients, today announced the recruitment of Gunilla Mickelsson as Global Market…
Sedana Medical AB (publ) has completed a directed new share issue of approximately SEK 112 million directed to institutional investors
Regulatory
Sedana Medical AB (publ) (”Sedana Medical” or the ”Company”), today announces that the Company has successfully completed a directed new share issue of approximately SEK 112 million.
Sedana Medical AB (publ) intends to undertake a directed new share issue
Regulatory
Sedana Medical AB (publ) (”Sedana Medical” or the ”Company”) today announces its intention to execute a directed new share issue to Swedish and international investors (the ”Private Placement”). The Company has appointed Pareto Securities AB (”Pareto…
Bulletin from annual general meeting in Sedana Medical AB (publ)
Regulatory
Sedana Medical AB (publ) held the annual general meeting on 22 May 2018 in Stockholm. Below follows a summary of the resolutions that were made during the meeting.
Sedana Medical to host conference call to provide first quarter 2018 business update
Non-regulatory
On May 22, 2018, at 12:30 pm CET, Sedana Medical AB (publ) (Sedana Medical or the Company) will publish its interim report for the first quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will in…